Contribution of hepatitis B virus X protein-induced aberrant microRNA expression to hepatocellular carcinoma pathogenesis

Zhiyuan WEI1,2,*, Xiaohe SHEN3,*, Bing NI2,4, Gaoxing LUO5, Yi TIAN2,†, Yi SUN1,**
1Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, P. R. China
2Institute of Immunology, PLA, Army Medical University (Third Military Medical University), Chongqing, P. R. China
3Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, Shanxi, P. R. China
4Department of Pathophysiology and High Altitude Pathology, Army Medical University (Third Military Medical University), Chongqing, P. R. China

Abstract: The hepatitis B virus-encoded X (HBX) protein plays important roles in Hepatocellular carcinoma (HCC). Previous studies have demonstrated that HBX can induce alterations in the expression of numerous microRNAs (miRNAs) involved in the carcinogenesis of various tumors. However, the global profile of liver miRNA changes induced by HBX has not been characterized. In this study, we conducted a miRNA microarray analysis to investigate the influence of HBX on the expression of total miRNAs in liver in relation to HCC. Comparative analysis of the data from human normal liver cells (L02) and human HCC cells (HepG2), with or without HBX, identified 19 differentially expressed miRNAs, including 5 with known association to HBX. Target gene prediction for the aberrantly expressed miRNAs identified a total of 304 potential target genes, involved in sundry pathways. Finally, pathway analysis of the HBX-induced miRNAs pathway showed that 5 of the total miRNAs formed an internetwork, suggesting that HBX might exert its pathological effects on hepatic cells through functional synergy with miRNAs that regulated common pathways in liver cells. Therefore, this work provides new insights into the mechanisms of HCC as well as potential diagnostic markers or therapeutic targets for use in clinical management of HCC.

Key words: Hepatocarcinoma, HBX, miRNA, internetwork

1. Introduction
Hepatocellular carcinoma (HCC) remains one of the most lethal malignant cancers worldwide, ranking third among all the cancers for annual cancer mortality. Chronic infection with hepatitis B virus (HBV) is a major etiological risk for the development and progression of HCC (Kew, 2010). The mechanisms underlying HBV-induced malignant transformation remain a topic of intense research, and recent studies have revealed that the hepatitis B virus-encoded X (HBX) protein, which is essential for virus replication in vivo, plays an important role in hepatocarcinogenesis (Chen et al., 1993).

HBX-induced HCC involves disruption of the signaling pathways that control normal physiological functions in the host cells (Tian et al., 2013). For instance, the HBX protein can serve as a substrate of protein kinase B (Akt kinase) (Srisuttee et al., 2012), the subsequent dysregulation of which affects pathways that mediate cell survival and oncogenic transformation (Vivanco and Sawyers, 2002). Ectopic expression of HBX in human normal liver cells (LO2, stably transfected with HBX) leads to significantly increased activity of the multifunctional Notch1 signaling pathway and marked inhibition of apoptosis via the caspase 9-caspase 3 signaling pathway (Sun et al., 2014). Furthermore, HBX can interrupt the DNA repair process through its regulation of the transactivating function of p53 (Lee et al., 2005).

HBX can also induce aberrant expression of microRNAs (miRNAs), and this infection-related process has been shown to contribute to the pathogenesis of HCC (Esteller, 2011; Xu et al., 2013; Wu et al., 2014). miRNAs can function on either oncogenes or tumor suppressor genes to mediate tumorigenesis (Wei et al., 2015). The presence of HBX has been shown to be significantly associated with alterations in the host miRNA profile (Trang et al., 2008). For example, it suppresses the expression of miRNA-
148a, which results in the activation of AKT and of the extracellular signal-regulated kinase signaling pathway, ultimately leading to the activation of rapamycin and the subsequent promotion of cancer cell proliferation and metastasis, as shown in a mouse model (Xu et al., 2013). Recent studies have demonstrated HBX inhibition of the expression of miRNA-15b, which otherwise directly targets the fucosyltransferase 2 enzyme and increases the levels of the tumor-associated antigen Globo-H, ultimately enhancing HCC cell proliferation (Wu et al., 2014). HBX has also been shown to decrease the inhibitory effect of miRNA-205 on carcinogenesis by down-regulating the expression of miRNA-205 in the livers of HBX transgenic mice (Zhang et al., 2013).

Although several reports have provided evidence for a relationship between HBX, specific miRNAs, and target genes (Esteller, 2011; Xu et al., 2013; Zhang et al., 2013; Wu et al., 2014), the regulation of the global miRNA profile in liver cells by HBX in relation to the development and progression of HCC remains to be fully clarified. Therefore, this study was designed to use microarray analysis to investigate the alteration of miRNA profiles in L02 and HepG2 cell lines that were transfected with HBX-expressing lentivirus, and to compare the results to those from control L02 and HepG2 cells transfected with empty lentivirus. The resulting set of differentially expressed miRNAs were subject to target gene prediction and pathway analysis. Finally, the internetwork of the HBX-induced miRNAs pathway was investigated to determine whether HBX-induced mRNAs function in a synergistic manner to support the pathogenesis of HCC.

2. Materials and methods

2.1. Cell lines
L02, HepG2, and HepG2.2.15, which was stably transfected with 2.1-fold HBV genome DNA, were permissible to HBV proliferation in cells (Sells et al., 1987) (all from the Chinese Academy of Sciences). The cells were cultured in a complete growth medium supplemented with 10% fetal bovine serum in a humidified atmosphere with 5% CO₂ and a temperature of 37 °C.

2.2. Tissues
All the patients underwent surgical resection of primary HCC at the Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University (Third Military Medical University). The HCC tissues and the adjacent tissues were diagnosed by pathological identification of the Department of Pathology, Southwest Hospital. Patient-derived HCC tissues were obtained from patient tumor specimens with informed consent according to the protocols approved by the Institutional Review Board of the Southwest Hospital, Army Medical University (Third Military Medical University) (Chongqing, China).

2.3. Lentivirus-mediated transfection of HBX
The cells were seeded into 24-well plates at a density of 1 × 10⁴ cells/well. After 1 day of culture, the indicated combinations and multiplicity of infection (MOI) ratios of control (empty vector) or recombinant lentiviruses expressing HBX and GFP were applied to the cells according to the procedure reported by Chiang et al. (2014). The virus-infected L02 and HepG2 cells were then cultured in fresh 24-well plates for the indicated times, with medium exchange every other day.

2.4. Total RNA extraction, qRT-PCR, and microarray analyses
Total RNA was extracted from the cells and clinical tissues (from Southwest Hospital, China) by using the RNAiso reagent (TaKaRa, Japan). The miRNA microarray was designed and detected by the Kangchen Company (China). To validate the microarray findings, cDNA synthesis was performed using a PrimeScript RT Reagent Kit (TaKaRa) and the products were amplified by qPCR with SYBR Premix Ex Taq II (TaKaRa), the appropriate miRNA primers (TianGen Company, Beijing, China) and the Stratagene Mx3000P real-time PCR system (Agilent Technologies, CA, USA). The qPCR-detected expression levels were normalized to those of the snRNA U6 endogenous control using the 2^{−∆∆Ct} method.

2.5. Immunofluorescent and immunohistochemical staining
For immunofluorescent staining, the cells were simultaneously incubated with the primary rabbit antihuman hepatitis B virus X antigen antibody (Abcam, UK) and the secondary antirabbit IgG antibody (Abcam). For immunohistochemical staining, endogenous peroxidase activity was quenched by incubating the slide with 0.6% hydrogen peroxide, after which the slides were washed in phosphate-buffered saline and exposed to the primary rabbit antihuman hepatitis B virus X antigen antibody (Abcam). After the incubation, the slides were washed and exposed to the secondary Alexa Fluor® 555 conjugated antirabbit IgG (Abcam). Then, the slides were washed and exposed to the avidin–biotin complex for 30 min at room temperature. Also, the immunoreactions were detected by use of the diaminobenzidene reagent (Sigma, China).

2.6. Target gene prediction
Microcosm (http://www.ebi.ac.uk/enright-srv/microcosm/), miRanda (http://microRNA.org/), and TargetsScan (http://www.targetscan.org) programs, which apply computational algorithms based on base-pairing rules for miRNA binding to mRNA target sites, the location of binding sequences within the 3’-UTR of the target, and the conservation of target binding sequences within the related genomes, respectively, were used to predict
target genes for the differentially expressed miRNAs. The genes identified by these software programs were taken as target genes. The predicted genes were subjected to pathway analysis (http://www.kegg.jp/) using the standard enrichment computation method.

2.7. Gene pathway analysis
The functional analysis of the predicted genes was carried out by mapping to KEGG pathways (http://www.kegg.jp/). The EASE-score, the Fisher’s P-value, or the hypergeometric P-value was calculated to determine the significance of the pathway’s correlation with the conditions. The lower the P-value, the more significant the pathway’s correlation; a P-value cut-off of 0.05 was used.

2.8. miRNA-pathway analysis
Although 19 significantly differentially expressed miRNAs were found, only when the overlap coefficient was ≥0.5 and the overlap numbers of the pathways of miRNA-targeted gene was >3, were the eligible miRNAs selected for inclusion in the analysis of the miRNA-pathway network. This strategy of miRNA selection was represented by the following equation: given the sets X and Y, and the cardinality operator | | where | X | equals the number of elements within the set X, the overlap coefficient was defined as overlap (X, Y) = | X ∩ Y | / min(|X|, |Y|) (Merico et al., 2010). X remains to one collection of the target gene, while Y remains to another collection of the target gene. The miRNA-pathway network analysis was performed by the CytoScape software.

2.9. Statistical analysis
Data generated from the microarray was imported to Microsoft Excel. After normalizing the signal of each miRNA by using global average normalization as described by Bilban et al. (2002), the expression level of each miRNA was calculated. Student’s t-test was performed to estimate between-group differences. All the statistical analyses were performed using the GraphPad Prism software 5.0. Statistical significance was defined by a P-value of <0.05. For each miRNA, the difference between HCC and normal liver cells was considered significant if the fold-change was >2 or <0.5 and the P-value was <0.05.

3. Results
3.1. HBX-induced aberrant miRNAs in normal liver cells and HCC cells
To define the global profile of HBX-induced alterations in miRNA of liver cells in relation to HCC, we first established HBX-overexpression cell lines by infecting L02 and HepG2 cells with empty lentivirus vector or recombinant lentivirus, respectively. The qPCR analysis indicated that HBX mRNA was elevated thousands of times higher in the L02 cells transfected with HBX-expressing lentivirus, as compared with the L02 cells transfected with the empty lentivirus (Figure 1A). The qRT-PCR results were similar for the HepG2 cells, although the HBX mRNA expression level in the HepG2-HBX cells was lower than that in the HepG2.2.15 cells (Sells et al., 1987) (Figure 1A). The ectopic expression of the HBX protein, from the HBX gene encoded by the recombinant lentivirus vector, was verified in the transfected cells by immunohistochemical staining (Figure 1B). Immunofluorescent staining confirmed that the HBX protein was expressed in both nuclei and the cytoplasm, consistent with previous reports (Majano et al., 2001; Shirakata and Koike, 2003). The HepG2 cells that were transfected with empty lentivirus (lacking the HBX gene, but encoding the GFP gene) did not express any HBX protein that was detectable by either immunohistochemistry or immunofluorescence, although the GFP protein was appropriately expressed (Figure 1C).

Upon the microarray analysis of these four cell lines (L02-empty lentivirus, L02-recombinant lentivirus (L02-HBX), HepG2-empty lentivirus, HepG2-recombinant lentivirus (HepG2-HBX)), miRNAs with ≥2-fold-change differential expression were selected as the candidate target miRNAs of HBX. The up- and downregulated candidate target miRNAs were presented in Figure 2, and were assessed to determine the key HBX-induced miRNAs that may play pivotal roles in both normal liver and HCC cells. The comparison of the differential miRNA profiles of the L02-HBX cells and the HepG2-HBX cells showed 15 miRNAs that were simultaneously decreased (2- to 36-fold) and 4 miRNAs that were simultaneously increased (2.0- to 10.6-fold) in these cells (Table).

3.2. Validation of candidate miRNAs induced by HBX
In order to validate the microarray results, we selected three miRNAs for qPCR verification. The results showed that the expression levels of miRNA-21, miRNA-211, and miRNA-125b—among the 15 downregulated candidate miRNAs (Table)—were decreased about 0.5-, 0.46-, and 0.378-fold-change, respectively, as compared to the vectors alone. These results were consistent with the microarray results (Figure 3A). Furthermore, the expression levels of these three miRNAs in surgery specimens from 10 HCC patients with HBV infection were also significantly reduced compared to the levels detected in paired adjacent nontumor tissues (Figure 3B); in addition, the level of HBX mRNA was significantly higher in the tumor tissues than the adjacent nontumor tissues (Figure 3C). These in vitro and in vivo results indicated that miRNA-21, miRNA-211, and miRNA-125b were downregulated in the presence of HBX, thus supporting the accuracy of the data generated from the microarray (Table).

3.3. Candidate target genes of miRNAs induced by HBX
Prediction analysis by three different computational algorithms identified 38,187, 9684, and 5459 target genes, respectively, as targets of the total set of HBX-altered
miRNAs. A total of 304 target genes overlapped among these three algorithms, as shown by the Venn diagram (Figure 4). The overlapping target genes included some important genes that have been previously verified by other studies in the literature, including B-cell lyphma-3 (BCL3) (Ahlqvist et al., 2013) and cytidine deaminase (CDA) (Zauri et al., 2015). The overlapping target genes also included many genes that have yet to be verified;
Figure 2. Differential expression of HBX-induced miRNAs in normal liver and HCC cells. Scatter plots of up- and downregulated miRNAs in control (x-axis) and HBX over-expressing (y-axis) cells. Each point in the figure represents a single miRNA. The red points represent upregulated miRNAs with a ratio of >2. The black points represent equally-expressed miRNAs with a ratio of ≥1/2 and ≤2. The blue points represent downregulated miRNAs with a ratio of <1/2.

Figure 3. Validation of miRNA expression by qRT-PCR. A: The relative expression of miRNA-21, miRNA-211, and miRNA-125b in L02 and HepG2 cells transfected with empty lentivirus (C) or recombinant lentivirus (HBX). B: The relative expression level of miRNA-21, miRNA-211, and miRNA-125b in HBV-infected HCC samples (Ca) and the adjacent tissues (Aj). C: The relative HBX mRNA expression in HBV-infected HCC samples and the adjacent tissues. *P < 0.05; **P < 0.001.
therefore, we selected two candidate target genes—BCL2L10 and ARHGAP10—to verify their expression in vitro and in vivo.

BCL2L10 was identified as a potential target of miRNA-125b, and ARHGAP10 was identified as a potential target of miRNA-21 and miRNA-211. According to previous reports, BCL2L10 can induce cell apoptosis through a mitochondrial signaling pathway under conditions of gastric cancer (Xu et al., 2011) and ARHGAP10 can contribute to the adherens junction (Sousa et al., 2005). By using the qRT-PCR assay, we found that the marked decrease of the three miRNAs cited above as observed in HepG2-HBX and L02-HBX cell lines (Figure 3) was accompanied by significant up-regulation of both BCL2L10 and ARHGAP10 (Figure 4B and 4C). In vivo analysis of liver tissues confirmed this finding, with the mRNA expression level of BCL2L10 and ARHGAP10 being shown as significantly increased in HBV-infected liver tissues (Figure 4D).

3.4 Analysis of HBX-induced miRNA target genes according to KEGG pathways

Because signaling pathways play key roles in many biological and pathological events, we performed enrichment analysis of the KEGG pathways for each of the HBX-induced miRNA target genes. The top 10 enriched KEGG pathways for the genes related to the upregulated miRNAs were involved in chronic myeloid leukemia, nonsmall cell lung cancer, glioma, bladder cancer, long-term potentiation, the MAPK signaling pathway, endometrial cancer, the ErbB signaling pathway, acute myeloid leukemia, and the mTOR signaling pathway (Figure 5A). For the genes related to the downregulated miRNAs, the top 10 enriched KEGG pathways for the target genes were involved in the neurotrophin signaling pathway, pathways in cancer, transcriptional misregulation in cancer, the MAPK signaling pathway, axon guidance, the FoxO signaling pathway, proteoglycans in cancer, the Hippo signaling pathway, focal adhesion,

Table. Fold-changes and chromosome locations of miRNAs showing differential expression in both HepG2-HBX and L02-HBX cells.

| Name          | Fold-change | Location       |
|---------------|-------------|----------------|
| Hsa-miR-4436b | 10.57       | Chr2: 110086433-110086523 |
| Hsa-miR-5584  | 2.521       | Chr1: 44545493-44545552    |
| Hsa-miR-663a  | 2.09        | Chr20: 26208186-26208278   |
| Hsa-miR-4776  | 2.00        | Chr2: 212926257-212926336 |

| Name          | Fold-change | Location       |
|---------------|-------------|----------------|
| Hsa-miR-4796  | 0.496919918 | Chr3: 114743445-114743525 |
| Hsa-miR-211   | 0.470588235 | Chr15: 31065095-31065116  |
| Hsa-miR-25    | 0.439732143 | Chr7: 100093560-100093643  |
| Hsa-miR-4489  | 0.428776978 | Chr11: 65649192-65649253   |
| Hsa-miR-4447  | 0.411417323 | Chr3: 116850277-116850367  |
| Hsa-miR-622   | 0.406779661 | Chr13: 90231182-90231277   |
| Hsa-miR-4283  | 0.327731092 | Chr7: 56955785-56955864    |
| Hsa-miR-132   | 0.322946176 | Chr17: 2049908-2050008     |
| Hsa-miR-219-2 | 0.3125      | Chr9: 128392618-128392714  |
| Hsa-miR-21    | 0.310725552 | Chr17: 59841266-59841337    |
| Hsa-miR-4638  | 0.300438393 | Chr15: 181222566-181222633 |
| Hsa-miR-1909  | 0.294372294 | Chr19: 1816159-1816238     |
| Hsa-miR-125b-1| 0.244444444 | Chr11: 122099757-122099844 |
| Hsa-miR-632   | 0.227272727 | Chr17: 32350109-32350202   |
| Hsa-miR-26a-2 | 0.125348189 | Chr12: 57824609-57824692   |
3.5 Pathways-based miRNAs internetwork induced by HBX

In order to directly show the roles of differentially expressed miRNAs on pathways, we generated a network between the miRNAs and potential pathways by using the CytoScape software. The miRNAs were selected only when the overlap-coefficient was ≥0.5 and the overlap numbers of the pathways of miRNA-targeted gene were ≥3; the eligible miRNAs were thus included to make up the pathways-based miRNAs internetwork. A total of 5 miRNAs were identified as interacting with others and found to mediate at least 3 common pathways (Figure 6). Among these, only miRNA-663a, one of the total four upregulated miRNAs fitting the criteria for this analysis (overlap-coefficient of ≥0.5 and overlap numbers of the pathways of miRNA-targeted gene of ≥3), formed an internetwork with the other miRNAs. In addition, among the 15 downregulated miRNAs that fit the criteria for this analysis, only miRNA-21, miRNA-211, miRNA-25, and miRNA-622 were involved in the network (Figure 6).
4. Discussion
In the present study, we performed microarray to investigate the HBX-induced differential expression pattern of miRNAs in human liver cells in relation to HCC. We identified a total of 19 miRNAs that showed significant changes in expression following ectopic HBX induction. Five of the 19 miRNAs (miRNA-132, miRNA-219, miRNA-125b, miRNA-26a, and miRNA-21) had been previously demonstrated to be associated with HCC (Wei et al., 2013; Zhou et al., 2014; Song et al., 2015; Zhou et al., 2015). Based on the KEGG pathway analysis, we found that the target genes of these miRNAs were closely associated with tumor-related biological processes (Figure 5). We also demonstrated in this study that HBX might exert pathological effects through miRNAs that target common pathways in hepatic cells (Figure 5).

Some of the HBX-induced miRNAs and their target genes predicted in the current study were mapped for their putative cooperation with each other in liver cells. In particular, 5 of the miRNAs—miRNA-663a, miRNA-21, miRNA-211, miRNA-25, and miRNA-622—had the potential to regulate common pathways in conjunction with the others, which were involved in several cancer-related pathways including colorectal cancer, gastric cancer, and HCC (Guo et al., 2011; Fang et al., 2015; Song et al., 2015; Xu et al., 2015) (Figure 6).

Therefore, this study provides new potential markers of clinical diagnosis and/or therapeutic targets of HCC.

Acknowledgments
This study was funded by grants from the General Program of NSFC (Nos. 31670889 and 31200668).

Figure 5. KEGG pathway analysis of target genes of the HBX-induced differentially expressed miRNAs. A, B: The top 10 enriched pathways for the upregulated and downregulated miRNAs, respectively.
Figure 6. HBX-induced miRNAs internetwork analysis. The red square nodes represent the eligible miRNAs; the green circular nodes represent the specific pathways (function terms). The arrows indicate the direction of relationships.
References

Ahlqvist K, Saamarthy K, Syed Khaja AS, Bjartell A, Massoumi R (2013). Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer. Oncogene 32:1601-1608.

Bilban M, Buehler LK, Head S, Desoye G, Quaranta V (2002). Normalizing DNA microarray data. Curr Issues Mol Biol 4: 57-64.

Chen HS, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, Purcell RH, Miller RH (1993). The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 67: 1218-1226.

Chiang TS, Yang KC, Chiou LL, Huang GT, Lee HS (2014). Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha. PloS One 9: e94885.

Esteller M (2011). Non-coding RNAs in human disease. Nat Rev Genet 12:861-874.

Fang Y, Sun B, Li Z, Chen Z, Xiang J (2016). MiR-622 inhibited colorectal cancer occurrence and metastasis by suppressing K-Ras. Mol Carcinogene 55: 1369-1377.

Guo XB, Jing CQ, Li LP, Zhang L, Shi YL, Wang JS, Liu JL, Li CS (2011). Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting p15Ink4b. World J Gastroentero 17: 1895-1902.

Kew MC (2010). Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol 58: 57-64.

Lee AT, Ren J, Wong ET, Ban KH, Lee LA, Lee CG (2005). The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. J Biol Chem 280: 33525-33535.

Majano P, Lara-Pezzi E, Lopez-Cabrera M, Apolinario A, Moreno-Otero R, Garcia-Monzon C (2001). Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor kappaB-binding site: evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology 34: 1218-1224.

Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010). Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PloS One 5: e13984.

Sells MA, Chen ML, Acs G (1987). Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. P Natl Acad Sci USA 84: 1005-1009.

Shirakata Y, Koike K (2003). Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. J Biol Chem 278: 22071-22078.

Song WH, Feng XJ, Gong SJ, Chen JM, Wang SM, Xing DJ, Zhu MH, Zhang SH, Xu AM (2015). microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma. Cancer Biol Ther 16: 1754-1763.

Sousa S, Cabanaud C, Archambaud C, Collard F, Lemichez E, Popoff M, Boisson-Dupuis S, Gouin E, Lecuit M, Leigrain P, Cossart P (2005). ARHGAP10 is necessary for alpha-catennin recruitment at adherens junctions and for Listeria invasion. Nat Cell Biol 7: 954-960.

Srisuttee R, Koh SS, Malila S, Moon J, Cho IR, Jhun BH, Horio Y, Chung YH (2012). SIRT1 sensitizes hepatocellular carcinoma cells expressing hepatitis B virus X protein to oxidative-stress-induced apoptosis. Biochem Bioph Res Co 429: 45-50.

Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B (2014). Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncol Rep 31: 933-939.

Tian Y, Yang W, Song J, Wu Y, Ni B (2013). Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol 33: 2810-2816.

Trang P, Weidhaas JB, Slack FJ (2008). MicroRNAs as potential cancer therapeutics. Oncogene 27 Suppl 2: S52-57.

Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.

Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, Liu R, Wu Z (2013). Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 25: 1037-1043.

Wei Z, Gao W, Wu Y, Ni B, Tian Y (2015). Mutual interaction between BCL6 and microRNAs in T cell differentiation. RNA Biol 12: 21-25.

Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY, Yu YL (2014). Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. Int J cancer 134: 1638-1647.

Xu JD, Cao XX, Long ZW, Liu XP, Furuya T, Xu JW, Liu XL, De Xu Z, Sasaki K, Li QQ (2011). BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells. J Pathol 223: 400-409.

Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K et al. (2013). Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123: 630-645.

Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C (2016). MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett 371: 171-181.

Zauri M, Bertridge G, Thezenas ML, Pugh KM, Goldin R, Kessler BM, Kriaucionis S (2015). CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524: 114-118.
Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, Gao Y, Zhang S, Lu Z, Ye L, Zhang X (2013). Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia 15: 1282-1291.

Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li G, Xie J, Chen P (2014). A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Canc Res 30: 33-55.

Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, Jia YL et al. (2015). MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology 62: 801-815.